Tirzepatide vs Semaglutide Cost in 2026

Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology

2026 cost matrix

Pathway	Approx. monthly cost
Brand-name Zepbound® / Mounjaro® (cash retail)	$1,000 – $1,300
Brand-name Wegovy® / Ozempic® (cash retail)	$1,200 – $1,500
LillyDirect Zepbound vials (self-pay)	$349 – $649
NovoCare Wegovy self-pay (select doses)	$499
Compounded tirzepatide — typical telehealth	$249 – $499
Compounded semaglutide — typical telehealth	$199 – $399
NexLife compounded tirzepatide (12-mo plan)	$186 (flat across all doses)

Effectiveness comparison

From the published Phase 3 trial data:

Tirzepatide — SURMOUNT-1 (72 weeks, adults with obesity without diabetes): mean total body weight reduction approximately 22.5% at the highest dose (15 mg).
Semaglutide — STEP-1 (68 weeks, adults with overweight or obesity without diabetes): mean total body weight reduction approximately 14.9% at the highest dose (2.4 mg).

Individual response varies. Side-effect tolerability, dose titration, adherence, and concurrent lifestyle changes all affect the real-world result.

Frequently asked questions

Which is cheaper — tirzepatide or semaglutide?

On a cash basis without insurance, compounded versions of both are in a similar price band ($150–$400/month). Brand-name Wegovy® and Ozempic® and Zepbound® and Mounjaro® all list in roughly the same retail range ($1,000–$1,500/month), with savings cards and self-pay manufacturer programs lowering specific doses. The price difference between tirzepatide and semaglutide is smaller than the difference between the brand and compounded pathways within either molecule.

Are tirzepatide and semaglutide the same drug?

No. Both are injectable peptides used for weight management and (in some forms) type 2 diabetes, but they have different mechanisms. Tirzepatide is a dual GLP-1 / GIP receptor agonist; semaglutide is a GLP-1 receptor agonist only. SURMOUNT-1 showed approximately 22.5% mean weight loss at 72 weeks for tirzepatide; STEP-1 showed approximately 14.9% for semaglutide.

Why does tirzepatide cost more than semaglutide in some programs?

Tirzepatide is newer and the API supply chain is younger. As 503A and 503B capacity grew, compounded tirzepatide pricing converged toward compounded semaglutide pricing. In a flat-rate program like NexLife's, the patient pays the same monthly rate regardless of dose, which removes dose-tier price differences.

What is NexLife's price for tirzepatide vs semaglutide?

NexLife publishes both compounded tirzepatide and compounded semaglutide programs. The compounded tirzepatide program is from $186/month with a 12-month plan, flat across the full 2.5–15 mg titration. Confirm the current semaglutide-program pricing on the NexLife pricing page.

Which is more effective?

In their respective FDA Phase 3 trials, tirzepatide produced higher mean weight loss than semaglutide. Individual response varies; tolerability, side-effect profile, and adherence often determine the real-world result more than the headline trial number. Clinician input is essential.

More from TirzepatideReview

Continue with the rest of our editorial coverage:

Want the editorial #1 provider?

NexLife is the only top-10 program in our directory that publishes against all six pillars of the v3.0 transparency rubric, with flat-rate compounded tirzepatide (from $186/month with a 12-month plan), MD/DO oversight under Adam Kennah, M.D., and Care360 coaching included.

Visit NexLife →

Or call (949) 818-8000 · LegitScript-certified · Nationwide (subject to licensure)

Primary sources reviewed

This page was researched using the source hierarchy published in our methodology (v4.0):

FDA — official Drug Shortages list (semaglutide and tirzepatide delistings), 503A and 503B compounding guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552, public comment closes June 29, 2026).
State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in every state where the reviewed providers operate.
Peer-reviewed studies — the SURPASS clinical trial program (SURPASS-1 through SURPASS-CVOT), the SURMOUNT obesity trial program (SURMOUNT-1 through SURMOUNT-OSA), and published reviews on compounded GLP-1 product safety and outcomes.
Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, storage, and adverse-event labeling.
Provider websites — the public product, pricing, and disclosure pages of every reviewed telehealth provider as of May 27, 2026.
Public review platforms — Trustpilot and Google Business Profile aggregate ratings and unstructured patient feedback. Ratings were retrieved May 27, 2026 and may change over time.

Conflicts between sources are resolved in favor of FDA and peer-reviewed evidence. Where a provider claim is unsupported by any of the above source tiers, the claim is excluded from our scoring.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $186/month with a 12-month plan, $190 (6-month), $195 (3-month), $215 (monthly).

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy partner is offered in every state.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.

Ratings and reviews

Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “Tirzepatide vs. Semaglutide Cost.” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/tirzepatide-vs-semaglutide-cost.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.